Summit Therapeutics (SMMT) Times Interest Earned (2017 - 2024)
Summit Therapeutics' (SMMT) quarterly Times Interest Earned came in at -$8.98 in Q4 2024, up 28.14% YoY from -$7.01 in Q1 2024, and up 62.23% on a QoQ basis from -$23.78 in Q3 2024.
Powered by 
Analysis
Summit Therapeutics (SMMT) Times Interest Earned (2017 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has 8 years of Times Interest Earned data on file, last reported at -$8.98 in Q4 2024.
- Quarterly Times Interest Earned rose 28.14% year-over-year to -$8.98 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$14.14 (up 59.11% YoY) and the FY2024 annual result came in at -$0.13, up 98.13% from the prior year.
- Times Interest Earned advanced to -$8.98 in Q4 2024, from -$23.78 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$4.46 in Q3 2020 to a low of -$626.78 in Q1 2021.
- A 5-year average of -$64.63 and a median of -$19.44 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned surged 88.1% — and 2024, when it tumbled 324.44%.
- Tracing SMMT's Times Interest Earned over 5 years: stood at -$45.32 in 2020, then gained by 27.88% to -$32.68 in 2021, then surged by 78.61% to -$6.99 in 2022, then plunged by 78.81% to -$12.5 in 2023, then climbed by 28.14% to -$8.98 in 2024.
- The last three Times Interest Earned figures came in at -$8.98 (Q4 2024), -$23.78 (Q3 2024), and -$19.22 (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Summit Therapeutics | 13.67 Bn | 12.98 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -7,290.44 |
| Sep 30, 2024 | -23.79 |
| Jun 30, 2024 | -19.22 |
| Mar 31, 2024 | -13.58 |
| Mar 31, 2020 | -311.56 |
| Dec 31, 2019 | -376.40 |
| Oct 31, 2019 | -306.13 |
| Jul 31, 2019 | -267.40 |
| Mar 31, 2019 | -286.18 |
| Oct 31, 2018 | -369.97 |
| Jul 31, 2018 | 55.49 |
| Apr 30, 2018 | -102.53 |
| Oct 31, 2017 | -64.91 |
| Jul 31, 2017 | -61.38 |
| Apr 30, 2017 | -58.97 |